Zetia Cost in Wyoming 2026: Ezetimibe Prices, Coverage, and Savings Options

What Does Zetia Actually Cost in Wyoming in 2026?

Wyoming residents have two very different numbers to keep in mind: the brand list price and the generic cash price. Merck's brand Zetia carries a manufacturer list price near $380 per month in 2026. Generic ezetimibe 10 mg, available from multiple manufacturers since 2017, brings that figure down to approximately $15 per month at retail pharmacies across Wyoming when paying cash or using a discount card.

The gap between those two figures is not accidental. When the Paragraph IV patent challenge succeeded and multiple generic manufacturers entered the U.S. market, retail prices for ezetimibe fell by more than 90% within 18 months. A 2021 analysis published in JAMA Internal Medicine found that generic entry consistently drove cholesterol-lowering drug prices below the 15-dollar threshold within two years of exclusivity loss. [1] That pattern holds for ezetimibe in Wyoming today.

Prices do vary by pharmacy. Walmart and Costco pharmacies in Cheyenne and Casper tend to quote $10 to $14 for a 30-day supply of generic ezetimibe 10 mg. Independent pharmacies in smaller Wyoming towns such as Riverton or Sheridan may quote $18 to $22 without a discount card. GoodRx and similar platforms can reduce those prices further at participating locations, sometimes below $10.

The FDA approved ezetimibe (Zetia) in 2002 for use as an adjunct to diet and statin therapy in adults with primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia. [2] The approved dose for all adult indications is 10 mg orally once daily, taken with or without food.

Patients who present a legitimate prescription receive the same drug regardless of whether they pay brand or generic pricing. The active molecule, mechanism, and bioavailability are identical under FDA bioequivalence standards. Choosing generic is clinically equivalent and costs roughly 25 times less in Wyoming.

How Ezetimibe Works and Why Cardiologists Prescribe It

Ezetimibe selectively inhibits NPC1L1, a transporter protein on the brush-border membrane of small intestinal enterocytes. Blocking NPC1L1 reduces dietary and biliary cholesterol absorption by roughly 54%, which in turn stimulates hepatic LDL-receptor upregulation and lowers circulating LDL-C. [3]

The IMPROVE-IT trial (N=18,144), published in the New England Journal of Medicine in 2015, remains the definitive outcomes evidence for ezetimibe. Patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. After a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the monotherapy arm. The primary composite endpoint (cardiovascular death, major coronary events, or stroke) occurred in 32.7% of combination patients versus 34.7% of placebo patients, an absolute risk reduction of 2 percentage points and a relative risk reduction of 6.4% (P<0.016). [4]

That trial answered a long-standing question about whether non-statin LDL lowering translates to clinical benefit. The answer was yes, at least when added to background statin therapy in a high-risk post-ACS population.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD on maximally tolerated statin therapy who require additional LDL-C lowering, ezetimibe is reasonable as a first add-on therapy." [5] That wording places ezetimibe ahead of more expensive PCSK9 inhibitors on the treatment ladder for most patients.

Ezetimibe's safety profile is favorable. The most common adverse effects are upper respiratory infection, diarrhea, and arthralgia, each occurring at rates within 1 to 2 percentage points of placebo in IMPROVE-IT. [4] Hepatotoxicity is rare; the FDA label advises periodic liver function monitoring only when ezetimibe is combined with a statin, consistent with the statin's own labeling requirements. [2]

Wyoming Medicaid Coverage for Zetia and Ezetimibe

Wyoming Medicaid does not cover brand Zetia or generic ezetimibe for most enrollees under the current 2026 formulary. This is a meaningful access barrier in a state where roughly 74,000 residents are enrolled in Medicaid and a significant proportion carry cardiovascular risk factors that would otherwise make ezetimibe a guideline-supported option. [6]

Wyoming's Medicaid program operates under a preferred drug list (PDL) that prioritizes statins as the first-line lipid-lowering class. Generic statins such as atorvastatin and rosuvastatin are fully covered. Ezetimibe is classified as non-preferred, and prior authorization requests for it are routinely denied unless a patient has documented statin intolerance combined with a compelling clinical rationale accepted by the Medicaid pharmacy director.

The practical consequence: most Wyoming Medicaid patients who need ezetimibe must access it through a cash-pay or assistance route rather than through their Medicaid benefit. At $15 per month for the generic, out-of-pocket cost is manageable for many, but the formulary exclusion remains a structural gap worth flagging to your prescriber.

Patients should ask their physician to submit a prior authorization regardless, citing the ACC/AHA 2022 guideline language and the IMPROVE-IT absolute risk reduction data. [4] A small percentage of PAs do succeed, particularly for patients with familial hypercholesterolemia, homozygous FH, or documented statin myopathy. Wyoming Medicaid decisions can be appealed within 30 days of denial, and the State Office of Rural Health sometimes assists with appeal documentation.

Children with homozygous FH may qualify under Wyoming KidsCare (CHIP) with additional documentation, as that program uses a slightly different PDL than standard adult Medicaid.

Is Compounded Ezetimibe Legal in Wyoming?

Yes. Compounded ezetimibe is legal in Wyoming when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare drug preparations for individual patients when a licensed practitioner issues a prescription that is not commercially available in the exact needed form or when there is a documented clinical rationale for compounding. [7]

Wyoming adopted the NABP Model Pharmacy Act framework and licenses its compounding pharmacies through the Wyoming State Board of Pharmacy. A 503A pharmacy in Wyoming may compound ezetimibe into custom doses, alternative delivery vehicles, or combination formulations not available commercially. The pharmacy must use an FDA-registered bulk drug substance supplier, and the preparation must comply with USP Chapter 795 standards for non-sterile compounding.

The more complex question is cost. Several telehealth platforms that serve Wyoming patients have partnerships with 503A pharmacies that supply compounded ezetimibe at little or no cost to the patient as part of a subscription-based cardiovascular care model. In practice, a qualifying patient who enrolls in such a program may access compounded ezetimibe for $0 per month, compared to $15 for the generic at retail. The tradeoff is that you are receiving a compounded preparation rather than an FDA-approved finished dosage form, which carries a small and theoretical quality-control difference.

The FDA does not recognize a clinical shortage of ezetimibe (the commercial product is widely available), so 503B outsourcing facilities may not compound it in bulk without a shortage designation. [8] The distinction matters: 503A is patient-specific and legal; 503B bulk compounding of ezetimibe without a shortage designation is not. Wyoming patients should confirm their compounding pharmacy holds a current Wyoming Board of Pharmacy 503A license before accepting a compounded product.

Insurance Coverage for Zetia in Wyoming: What to Expect

Private insurance coverage for ezetimibe in Wyoming depends entirely on the plan's formulary. Under ACA marketplace plans sold through Wyoming's federally facilitated exchange, generic ezetimibe appears on most Tier 2 or Tier 3 formularies, meaning a copay of $30 to $75 per month after deductible is common. Brand Zetia, when covered at all, typically sits on Tier 4 or Tier 5 with cost-sharing that can reach $100 to $200 per month even with insurance.

Employer-sponsored plans in Wyoming vary widely. Large employers in the energy and mining sectors generally use pharmacy benefit managers (PBMs) such as CVS Caremark or Express Scripts, both of which place generic ezetimibe on their national standard formularies. State employees covered by the Wyoming State Employees' Health Insurance Plan should check the current formulary booklet, as ezetimibe's tier placement shifted between plan years.

Medicare Part D enrollees in Wyoming should use the Medicare Plan Finder at cms.gov to compare formulary placements across available plans. In 2026, most Part D plans list generic ezetimibe at a Tier 2 preferred generic copay of $5 to $15 per month after the deductible phase. Brand Zetia on Part D is almost universally Tier 5 or non-formulary.

Step therapy requirements are common. Many Wyoming commercial plans require documented failure of at least one generic statin at maximally tolerated dose before approving ezetimibe coverage, even for the generic. The ACC/AHA 2022 guideline supports ezetimibe as add-on therapy rather than monotherapy, so step therapy denials based on "try a statin first" logic may not apply when the patient is already on a statin. [5] Your prescriber can submit a step therapy exception with the IMPROVE-IT citation and your current LDL-C level.

Telehealth Prescribing of Ezetimibe in Wyoming

Wyoming permits telehealth prescribing of ezetimibe without restriction for licensed practitioners who have established a valid patient-provider relationship. The Wyoming State Legislature codified telehealth parity under Wyoming Statute 26-52-102, and the Wyoming Board of Medicine recognizes audio-video encounters as sufficient to establish the clinical relationship required for prescribing Schedule V and non-scheduled medications including ezetimibe.

Ezetimibe is not a controlled substance, so it does not trigger the additional federal Ryan Haight Act requirements that apply to controlled medications. A Wyoming-licensed prescriber, or an out-of-state prescriber with a Wyoming license, may evaluate a patient via synchronous telehealth, review lipid panel results, and send a prescription to any Wyoming retail or mail-order pharmacy in a single visit. [9]

HealthRX clinicians follow a standard lipid-assessment protocol before initiating or continuing ezetimibe: a baseline fasting lipid panel, AST/ALT if the patient is on a concurrent statin, and a cardiovascular risk calculation using the ACC/AHA Pooled Cohort Equations. The 2018 ACC/AHA Blood Cholesterol Guideline specifies that ezetimibe should be considered for patients with LDL-C greater than or equal to 70 mg/dL despite maximally tolerated statin therapy and 10-year ASCVD risk of 7.5% or higher. [10]

A telehealth visit for lipid management in Wyoming typically costs $75 to $150 without insurance, or $0 to $30 with insurance under the ACA's preventive care provisions, depending on how the visit is coded. Several platforms offer subscription pricing that includes quarterly follow-up and lab interpretation.

The Cheapest Way to Get Ezetimibe in Wyoming

For most Wyoming residents without comprehensive drug coverage, the lowest-cost path in 2026 follows a short checklist.

Generic ezetimibe 10 mg at a cash-pay pharmacy remains the default starting point. At $15 per month, this is already affordable for many patients. Adding a GoodRx Gold membership (approximately $10 per month for individuals) brings the cost at participating pharmacies below $10, though the membership fee partially offsets the savings at that price point. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists ezetimibe 10 mg at $8.40 for 90 tablets as of early 2025, which equates to roughly $2.80 per month, and ships to Wyoming. [11]

Patients enrolled in telehealth cardiovascular programs that include 503A compounding partnerships may receive ezetimibe at $0 per month, though they should confirm pharmacy licensure and USP compliance as described above.

The Merck Patient Assistance Program (Merck Helps) provides brand Zetia at no cost to patients who meet income criteria (generally household income below 400% of the federal poverty level) and lack drug coverage. Applications are processed through the prescriber's office. Processing time is typically 4 to 6 weeks. [12]

NeedyMeds.org lists Wyoming-specific pharmaceutical assistance programs and is updated monthly; a search for "ezetimibe" returns current program statuses. The Partnership for Prescription Assistance (PPA) also aggregates manufacturer programs and can be accessed at pparx.org.

For patients who carry insurance but face high step-therapy barriers, requesting a formulary exception alongside an appeal citing the IMPROVE-IT outcomes data [4] and the ACC/AHA guideline [5] succeeds in a minority of cases but costs nothing to attempt. The written denial from the insurer is also required documentation for most manufacturer assistance programs, so filing the PA creates a useful paper trail regardless of outcome.

Ezetimibe Dosing, Monitoring, and What Your Wyoming Prescriber Will Check

The approved dose is ezetimibe 10 mg once daily, taken at any time with or without food. No dose adjustment is required for renal impairment of any severity, including end-stage renal disease. Mild hepatic impairment (Child-Pugh A) does not require adjustment, but the FDA label advises against use in moderate or severe hepatic impairment (Child-Pugh B or C) due to unknown exposure increases. [2]

Drug interactions are limited but real. Cyclosporine significantly increases ezetimibe plasma concentrations and requires clinical monitoring. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption by approximately 55% when co-administered; dosing ezetimibe at least 2 hours before or 4 hours after a bile acid sequestrant avoids this interaction. [2]

Monitoring after initiation follows the statin-plus-ezetimibe protocol from the ACC/AHA guideline: a fasting lipid panel at 4 to 12 weeks after initiation or dose change, then every 3 to 12 months thereafter depending on adherence and LDL-C trajectory. [5] A hepatic function panel is not required at baseline for ezetimibe monotherapy but is standard practice when combining with a statin.

LDL-C reductions with ezetimibe monotherapy average 15 to 22% from baseline in randomized trials. [3] Combined with a moderate-intensity statin, the incremental LDL-C reduction from adding ezetimibe is approximately 23 to 24 percentage points beyond what the statin alone achieves, as demonstrated in the SHARP trial (N=9,270), which also showed reduced major vascular events in patients with chronic kidney disease (rate ratio 0.83 to 95% CI 0.74 to 0.94, P<0.0021). [13]

Patients with LDL-C that remains above goal despite maximally tolerated statin plus ezetimibe should be evaluated for PCSK9 inhibitor therapy (evolocumab or alirocumab), inclisiran, or bempedoic acid. In Wyoming, access to PCSK9 inhibitors through private insurance requires step therapy documentation showing ezetimibe failure, making ezetimibe not just therapeutically appropriate but also a mandatory rung on the insurance access ladder for most patients.

Confirm your LDL-C target with your prescriber: for very high-risk ASCVD patients, the 2022 ACC/AHA guideline recommends an LDL-C goal of <55 mg/dL, and for high-risk primary prevention, <70 mg/dL.